ArticleMolecular biology reports2025
Neuroprotective effect of Continentalic acid by targeting NF-κB/Bcl-2 and oxidative stress signaling in traumatic brain injury in male BALB/c mice.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTraumatic brain injury (TBI) is characterized as a heterogeneous neurological disorder, which causes a variety of behavioral and functional impairments. Continentalic acid (CA), a diterpenoid acid obtained from Aralia continentalis, possesses anti-inflammatory, anti-apoptotic, and antioxidant properties.
methodsIn the current study we investigated the neuroprotective properties of CA in an experimental TBI model. An in vivo, weight-drop model of TBI was developed in male BALB/c mice. Following traumatic insult, CA (1, 10, and 50 mg/kg) was administered intraperitoneally for up to 14 days. To assess the protective effects of CA, we performed behavioral tests, spectroscopy, histopathology, and biochemical analyses.
resultsThe results revealed that CA significantly attenuated trauma-evoked neurological functions and improved mechanical as well as periorbital allodynia. CA also restored the structural and molecular composition of traumatized brain tissues. Similarly, CA reversed the histological changes in the cortex region of the traumatized brain sections and improved the neuronal count. CA administration also decreased the level of traumatic microbleeds in the brain. The expression levels of GFAP and Iba1 were significantly reduced by CA. Treatment with CA significantly reduced the expression of TLR-4, NF-κB, and increased the expression of IĸB-α regulatory protein. CA also downregulated the expression of cleaved caspase-3 protein and upregulated the expression of anti-apoptotic Bcl-2 protein and alleviated the DNA damage. CA dramatically improved the levels of GST, GSH, catalase, and SOD while concomitantly reducing NO and LPO levels. The levels of IL-1β and TNF-α were also reduced in the treatment group.
conclusionsThe results demonstrated that CA (50 mg/kg) exhibited neuroprotective activity in TBI by attenuating inflammation, neuronal apoptosis, and oxidative stress.
Indexed as
Identifiers
41313364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.